We are excited to share an update about Lexeo’s HEROIC PKP2 clinical trial.
Results to date highlights of this trial include the following:
- Completed enrollment of cohort 1 (low dose cohort) in the LX2020 HEROIC-PKP2 Phase 1/2 trial, with three people treated
- Early data, including safety and PKP2 protein expression, is expected in H1 2025. Key details include:
-
- To date, LX2020 has been generally well tolerated by study participants. No unexpected safety concerns or side effects related to the study drug have been observed
- Lexeo plans to start enrolling cohort 2 (higher dose cohort) after an independent Data Safety Monitoring Board reviews the data, which is standard practice in most clinical studies
To read the full press release, please click here.
Please note: The DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium do not endorse or encourage you to participate in any specific research study or therapy clinical trial. Given this disease has no known cure(s) we aim to provide this information to patients to review and decide independently if they would like to participate.
If you are considering participating in a research study or clinical trial please consult your medical team.